Rofecoxib, Merck, and the FDA.
Villalba
Lourdes
L
Witter
James
J
D002318:Cardiovascular Diseases / Q000139:chemically induced*; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects* / Q000266:history; D017277:Drug Approval / Q000266:history; D004345:Drug Industry / Q000266:history; D004348:Drug Labeling / Q000266:history; D049674:History, 21st Century; D006801:Humans; D007416:Intestinal Perforation / Q000517:prevention & control; D007783:Lactones / Q000009:adverse effects* / Q000266:history; D011358:Product Surveillance, Postmarketing; D013450:Sulfones / Q000009:adverse effects* / Q000266:history; D014481:United States; D014486:United States Food and Drug Administration
D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib